

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Robert SEEMAYER, et al.

Serial No.: 10/679,961

Group No. 1625

Filed: October 6, 2003

Examiner: P. Morris

For: PROCESS FOR THE PREPARATION OF (S,S)-CIS-2-BENZHYDRYL-3-BENZYLAMINOQUINUCLIDINE

Attorney Docket No.: U 014840-0

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450RECEIVED  
OCT 27 2004  
OFFICE OF PETITIONSINFORMATION DISCLOSURE STATEMENT

We draw the attention of the Examiner to the attached English-language version of an Action or International-type Search Report from a foreign office in respect of counterpart International Application No. US03/32275 that indicates the degree of relevance found by the foreign office. The Search Report makes consideration of any non-English art required. MPEP 609.

---

**CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10\***

(When using *Express Mail*, the *Express Mail* label number is **mandatory**;  
*Express Mail* certification is *optional*.)

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. 1.8(a)**

- ☒ with sufficient postage as first class mail.

**37 C.F.R. 1.10\***

- ☐ as "Express Mail Post Office to Addressee"  
Mailing Label No. \_\_\_\_\_ (mandatory)

**TRANSMISSION**

- ☐ transmitted by facsimile to the Patent and Trademark Office. to **(703) 872-9306**

Signature


Date: October 20, 2004John Richards

(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).  
"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Form PTO-1449 is also attached with reference copies despite prior citation of the U.S.  
patent.

Respectfully submitted,



---

John Richards  
c/o Ladas & Parry LLP  
26 West 61<sup>st</sup> Street  
New York, New York 10023  
Reg. No. 31053  
Tel. No. (212) 708-1915

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/32275

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07D 453/02

US CL : 546/133, 137

RECEIVED

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

OCT 27 2004

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 546/133, 137

OFFICE OF PETITIONS

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
STN STRUCTURE SEARCH, CAPLUS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SEWARD, E.M. et al.: Quinuclidine-based NK-1 antagonists I: 3-benzyloxy-1-azabicyclo[2.2.2]octanes. Bioorg. & Medicn. Chem. Lett. 1993, Vol. 3, No. 6, pages 1361-1366, especially compounds 16 and 17 on page 1363.	31-34
A	US 5,162,339 A (LOWE, J.A.) 10 November 1992 (10.11.1992), column 14, lines 45-57.	1-30

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

17 February 2004 (17.02.2004)

Date of mailing of the international search report

17 MAR 2004

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Authorized officer

Alan Roldman

Telephone No. (703)308-1235

Facsimile No. (703) 305-3230

FORM PTO-1449 U. S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)	ATTY. DOCKET NO.	SERIAL NO.
	U 014840-0	10/679,961
	APPLICANT	
	Robert SEEMAYER, et al.	
	FILING DATE	GROUP
	October 6, 2003	1625

U.S. PATENT DOCUMENTS					
EXAMINER INITIALS	REFERENCE DESIGNATION	DOCUMENT NUMBER	DATE	NAME	FILING DATE IF APPROPRIATE
	AA	5,162,339	10/1992	LOWE, III	
	AB				
	AC				
	AD				
	AE				
	AF				
	AG				
	AH				
	AI				
	AJ				
	AK				

**RECEIVED**  
**OCT 27 2004**  
**OFFICE OF PETITIONS**

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AL					
	AM					
	AN					
	AO					
	AP					

OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)		
AR	Seward, E. M., "Quinuclidine-Based NK-1 Antagonists I: 3-Benzoyloxy-1-Azabicyclo[2.2.2]Octanes", <i>Bioorganic &amp; Medical Chemistry Letters</i> , Vol. 3, No. 6, pp. 1361-1366, 1993	
AS		
AT		

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	